Interview with Selwyn Kahanovitz, CEO, Litha Healthcare Group Limited
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
Address: No 106, 16th Road, Midrand, 1686, Gauteng, South Africa
Tel: +27 11 516 1700
Web: http://www.lithahealthcare.co.za/
Litha Healthcare Group Limited is the result of the successful acquisition by Myriad Medical Holdings of Litha Healthcare Holdings (Proprietary) Limited in 2010.
Litha is a diversified healthcare company, with headquarters in Johannesburg, South Africa. Established in 1992 and with over 340 employees nationally, we are the only truly diversified Healthcare group listed on the Johannesburg Stock Exchange.
Litha Healthcare Group is divided into three Divisions;
Litha Biotech
Litha Medical
Litha Pharma
Within each Division there are 100% owned business units with the exception of The Biovac Institute which is a Public Private Partnership (PPP) between the SA Government and The Biovac Consortium.
Each Division is lead by a Divisional CEO. Litha Healthcare Group Limited provides healthcare solutions to hospitals, clinics, specialists pharmacies and general and allied practitioners either through distribution networks or directly.
The group’s diversified businesses include the following areas of healthcare:
Biotechnology : Vaccines
Medical devices : Consumables and Equipment
Pharmaceuticals : Generic, Ethical and Complimentary
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Having spent two months as the head of Novartis South Africa, what is your first assignment as General Manager, could you share with our readers what were the surprises for…
Mr. Miller, you have been Vice President and Managing Director of Mylan’s operations in South Africa since 2008. What mission were you assigned back then, and in those three years,…
South Africa carries one of the world’s most disproportionate disease burdens, the worst of so-called westernised diseases, such as cardiac disease, diabetes etc on the one hand and the developmental…
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Focus Reports is back in South Africa as part of a second set of reports on the BRICS. What would you say are the main changes in the market since…
South Africa is at the moment one of the world’s most exciting and dynamic markets at the moment as Mr. Omar Ehsan was telling us, the most exciting market he…
Could you introduce to our readers MC Pharma’s business model in the South African market as well as the main milestones in the company’s development over the recent years? MC…
Mr. Daniel, after working with Pfizer Australia, working in Hong Kong as Regional Marketing Director for the Asian operation and in Japan, you have been the first South African appointed…
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
See our Cookie Privacy Policy Here